In the last trading session, 1.71 million Corcept Therapeutics Inc (NASDAQ:CORT) shares changed hands as the company’s beta touched 0.45. With the company’s per share price at $70.49 changed hands at -$4.16 or -5.57% during last session, the market valuation stood at $7.44B. CORT’s last price was a discount, traded about -66.45% off its 52-week high of $117.33. The share price had its 52-week low at $20.84, which suggests the last value was 70.44% up since then. When we look at Corcept Therapeutics Inc’s average trading volume, we note the 10-day average is 3.53 million shares, with the 3-month average coming to 1.45 million.
Analysts gave the Corcept Therapeutics Inc (CORT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CORT as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Corcept Therapeutics Inc’s EPS for the current quarter is expected to be 0.14.
Corcept Therapeutics Inc (NASDAQ:CORT) trade information
Instantly CORT was in red as seen at the end of in last trading. With action -23.32%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 39.89%, with the 5-day performance at -23.32% in the red. However, in the 30-day time frame, Corcept Therapeutics Inc (NASDAQ:CORT) is 24.98% up. Looking at the short shares, we see there were 16.33 million shares sold at short interest cover period of 12.6 days.
The consensus price target for the stock as assigned by Wall Street analysts is 80, meaning bulls need an upside of 11.89% from its current market value. According to analyst projections, CORT’s forecast low is 80 with 80 as the target high. To hit the forecast high, the stock’s price needs a -13.49% plunge from its current level, while the stock would need to soar -13.49% for it to hit the projected low.
Corcept Therapeutics Inc (CORT) estimates and forecasts
Year-over-year growth is forecast to reach 34.12% up from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 177.93M. 4 analysts are of the opinion that Corcept Therapeutics Inc’s revenue for the current quarter will be 216.68M. The company’s revenue for the corresponding quarters a year ago was 146.81M and 163.8M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 21.20%. The estimates for the next quarter sales put growth at 32.28%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 9.89%. The 2025 estimates are for Corcept Therapeutics Inc earnings to increase by 37.80%, but the outlook for the next 5-year period is at 70.53% per year.
CORT Dividends
Corcept Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Feb-25.
Corcept Therapeutics Inc (NASDAQ:CORT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 11.44% of Corcept Therapeutics Inc shares while 81.32% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 91.82%. There are 81.32% institutions holding the Corcept Therapeutics Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 16.0391% of the shares, roughly 16.54 million CORT shares worth $537.36 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.2943% or 9.55 million shares worth $310.4 million as of 2024-06-30.
Among Mutual Funds, the top two as of Feb 28, 2025 were iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 5.94 shares estimated at $418.95 million under it, the former controlled 5.63% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.66% of the shares, roughly 2.8 shares worth around $197.69 million.
